To examine the mechanism of dual blockade of CDK4/6 and MEK on KRAS mutant CRC cells, cell growth was assessed with MTS assay after treatment with MEK162 and palbociclib for 72 hours. This evidence concerns the gene CDK4 and colorectal carcinoma.